Immunovant, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Immunovant, Inc. now
Current reporting with the operating signal separated from the noise.
Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating
The development tests whether Immunovant, Inc. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update
Investors are testing whether Immunovant, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Immunovant, Inc. to Host Investor Webcast on Phase 3 Study Results of Batoclimab in MG and Phase 2b Study in CIDP
The story matters when it changes Immunovant, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Immunovant, Inc. Reports Progress on IMVT-1402 Development and Financial Results for Fiscal Q3 2024
The story matters when it changes Immunovant, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest IMVT filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Immunovant, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →